Fuzheng Huayu Tablets Against Posthepatitic Cirrhosis

• Status: Completed
• Trial end date: 2009-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary purpose of the trial is adopted Fuzheng Huayu tablets against posthepatitic cirrhosis, and to build a standard evaluation system for efficacy of traditional Chinese medicine (TCM).

The second purpose is according to the international clinical guideline and the specialty of TCM to build a standard clinical trial regulation for traditional Chinese medicine.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai University of Traditional Chinese Medicine

Criteria

Inclusion Criteria:

• Clinical diagnosis of B Post hepatitic cirrhosis.

• Male or female patients between 18~65 years old.

• Written informed consent.

Exclusion Criteria:

• Child-Pugh C above 12, or ALT > 2×ULN, TBiL > 2×ULN, or combined with hepatic encephacopathy, Obstinate ascites, bleeding tendency, hepato-renal syndrome, or primary liver cancer.

• Combined with severe heart, gallbladder, kidney, endocrine system, hemopoietic system or nervous system disease.

• Deformed man by the law.

• Pregnancy or breast feeding women, or unwilling to have contraception.

• Irritability body constitution, or irritability of the Fuzheng Huayu Capsules.

• Enter other trials lately one month.

• Other cause of cirrhosis.